H. Lundbeck (LUN) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
19 Aug, 2026Executive summary
H1 2026 revenue grew 16% CER to DKK 13,588m, led by Vyepti (+46% CER) and Rexulti (+17% CER), with double-digit growth in the U.S. and Europe and strategic brands accounting for 77% of total revenue.
Underlying revenue growth was 13% CER after adjusting for a one-time inventory build.
Adjusted EBITDA rose 19% CER to DKK 4,765m, reflecting strong brand performance and operational efficiency.
Net profit increased 36% to DKK 2,806m, with adjusted EPS up 28% to DKK 3.70.
Net debt/EBITDA improved to 1.0x from 1.8x a year ago, reflecting continued deleveraging.
Financial highlights
Gross profit rose 15% CER to DKK 11,020m; gross margin at 81.1% (adjusted: 86.7%).
Adjusted EBITDA: DKK 4,765m (+19% CER, +13% DKK YoY); margin at 35.1%.
Free cash flow: DKK 2,316m, up 14% YoY, supporting ongoing debt reduction.
Operating expenses increased 12% CER, mainly from higher R&D costs (+24% CER), while sales and distribution costs were well controlled.
Net profit: DKK 2,806m (+36% YoY); adjusted EPS up 28% to DKK 3.70.
Outlook and guidance
FY 2026 guidance maintained: revenue growth 7–9% CER, adjusted EBITDA growth 8–14% CER; reported growth in DKK will be lower due to FX effects.
Adjusted gross margin expected around 87%; R&D costs DKK 5.6–5.9bn.
Net debt expected between DKK 4.0–5.0bn by year-end.
Inventory build in H1 expected to unwind in H2, with normalization anticipated.
Strategic brands, especially Vyepti and Rexulti, expected to remain primary growth drivers, with continued R&D investment.
Latest events from H. Lundbeck
- Upgraded guidance and late-stage catalysts support the 2027–2029 scale phase.LUN
Jefferies Global Healthcare Conference - Vyepti-led growth and stronger earnings lifted FY 2026 guidance as leverage fell.LUN
Q3 2026 - Vyepti-led growth lifted 9M results and FY 2026 guidance as leverage fell to 0.7x.LUN
Q3 2026 - Strategic-brand growth and pipeline investment support 2026 growth amid generic headwinds.LUN
Q4 2025 - Strong growth, innovation, and capital discipline drive long-term value and shareholder returns.LUN
Investor update - H1 2026 saw 16% CER revenue growth, strong brand and pipeline momentum, and guidance maintained.LUN
Q2 2026 - Bocunebart showed strong efficacy and safety in migraine prevention, advancing to Phase III.LUN
Study update - Q1 2026 saw 21% CER revenue growth, margin expansion, and upgraded full-year guidance.LUN
Q1 2026 - Transformative year with late-stage pipeline advances and disciplined capital allocation.LUN
43rd Annual J.P. Morgan Healthcare Conference